Adverse Events (Aes) as Potential Predictive Factors of Activity in Patients with Advanced Hepatocellular Carcinoma (Hcc) Treated with Atezolizumab plus Bevacizumab (Ab)
AuthID
P-00Z-QQW
P-00Z-QQW
© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service